All In Biotech

NDA 022087 · Galderma Labs Lp

Vectical

Calcitriol · Topical · Vitamin D3 Analog

Last checked: Nov 19, 2026Latest source record: Jul 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jan 23, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

162

20 Phase 3, 4 recruiting

FAERS reports

20,497

15,764 serious, 2,698 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2026.

VECTICAL Ointment is a vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adult and pediatric patients 2 years and older. ( 1.1 ) Limitations of Use The safety and effectiveness of VECTICAL Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. ( 1.2 ) 1.1 Indication VECTICAL Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. 1.2 Limitations of Use The safety and effectiveness of VECTICAL Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated.

Mechanism: The mechanism of action of calcitriol in the treatment of psoriasis has not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VECTICAL · CALCITRIOL 3MCG/GM · OINTMENT, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcitriol" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,485
  • diarrhoea1,212
  • off label use1,165
  • chronic kidney disease1,117
  • vomiting1,112
  • dyspnoea1,105
  • fatigue1,063
  • renal failure1,059
  • acute kidney injury975
  • death910
  • drug hypersensitivity883
  • drug ineffective831

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004179
2005245
2006171
2007190
2008282
2009390
2010395
2011413
2012543
2013567
2014561
2015896
20161,195
20171,385
20181,742
20192,334
20201,555
20211,454
20221,160
20231,215
20241,421
20251,212
2026992

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vectical (Calcitriol)

2024 spending

$998K

Beneficiaries

3,055

4,615 claims

Per beneficiary

$327

$1.97 per unit

View as table
YearSpending
2020$1,290,836
2021$1,431,082
2022$1,513,112
2023$1,533,566
2024$997,582

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 734 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.